<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437840</url>
  </required_header>
  <id_info>
    <org_study_id>DAN107606</org_study_id>
    <nct_id>NCT00437840</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809</brief_title>
  <official_title>A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help
      people stop smoking. This study will investigate if GSK598809 is safe and tolerated in people
      who smoke and will also look at blood levels of GSK598809 and nicotine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2007</start_date>
  <completion_date type="Actual">June 20, 2007</completion_date>
  <primary_completion_date type="Actual">June 20, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures: ECG, Vital Signs, Adverse Events</measure>
    <time_frame>for 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Blood levels of GSK598809 and nicotine</measure>
    <time_frame>for 96 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaires on nicotine craving</measure>
    <time_frame>for 24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tests on cognition (thinking)</measure>
    <time_frame>for 48 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Substance Dependence</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK598809</intervention_name>
    <description>GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.</description>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive single oral dose of matching placebo tablet to GSK598809.</description>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy adult male smoker between the ages of 18 and 50 years

          -  Body weight greater than 50kg and BMI between 18.5-29.9 kg/m2.

          -  No abnormalities on the medical, psychiatric or laboratory evaluation

          -  Smoke on average more than 20 but less that 40 cigarettes per day for the past year
             and not tried to give up in the 3 months before the study.

        Exclusion criteria:

          -  History of psychiatric disorder or sleep disorder.

          -  Receiving treatment for smoking cessation.

          -  Use tobacco products other than cigarettes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/DAN107606?search=study&amp;search_terms=DAN107606#rs</url>
    <description>Results for study DAN107606 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>safety,</keyword>
  <keyword>smoking,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

